# China NMPA Drug Inspection - Hebei Jinfang Pharmaceutical Co., Ltd. - Triamcinolone acetonide chloramphenicol solution

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hebei-jinfang-pharmaceutical-co-ltd/e421963f-1959-48ce-8e21-6d5c17d97ac7/
Source feed: China

> China NMPA drug inspection for Hebei Jinfang Pharmaceutical Co., Ltd. published December 28, 2020. Drug: Triamcinolone acetonide chloramphenicol solution. The Hebei Provincial Drug Administration published Drug Quality Bulletin No. 4 on December 28, 2020, revealing significa

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Hebei Province Drug Quality Bulletin (2020 Drug Supervision and Sampling Inspection No. 4)
- Company Name: Hebei Jinfang Pharmaceutical Co., Ltd.
- Publication Date: 2020-12-28
- Drug Name: Triamcinolone acetonide chloramphenicol solution
- Inspection Finding: The [content determination] item did not meet the requirements.
- Action Taken: Relevant drug regulatory authorities have taken control measures such as sealing and seizing in accordance with the law; they have filed cases to investigate illegal acts of producing and selling substandard products and taken necessary risk control measures.
- Summary: The Hebei Provincial Drug Administration published Drug Quality Bulletin No. 4 on December 28, 2020, revealing significant quality non-compliance identified during state-wide sampling inspections. Two specific manufacturers were cited for failing standards: Bozhou Huayun Traditional Chinese Medicine Pieces Co., Ltd. and Hebei Jinfang Pharmaceutical Co., Ltd. The violations involved a batch of Earthworm pieces from Bozhou Huayun that failed appearance testing due to insect infestation, and a batch of Triamcinolone acetonide chloramphenicol solution from Hebei Jinfang that failed content determination tests, indicating incorrect ingredient levels. These inspections were conducted under the 2020 provincial supervision plan and are governed by the Drug Administration Law of the People's Republic of China. Regulatory authorities have already implemented control measures, including seizing and sealing the substandard products. Mandatory follow-up actions include the formal investigation and prosecution of the involved enterprises for the illegal production and sale of substandard drugs. Additionally, authorities must establish risk control measures, investigate distribution channels for counterfeit products, and refer any suspected criminal activities to public security departments for further prosecution.

Company: https://www.globalkeysolutions.net/companies/hebei-jinfang-pharmaceutical-co-ltd/eb12445f-f7a6-47bb-a8b2-b8838bc9e068/